ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023
[Clinical value of plasma scaffold protein SEC16A in evaluating hepatitis B-related liver cirrhosis and hepatocellular carcinoma].
C Dong, C D Chang, D D Zhao, X X Zhang, P L Guo, Y Dou, S X Zhao, Y M Nan
Open access · greenAbstract readEnglish Abstract
In one paragraphArticle in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 2 institutions in 1 country.
C DongDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
C D ChangDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
D D ZhaoDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
X X ZhangDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
P L GuoDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
Y DouDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
S X ZhaoDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
Y M NanDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
Hebei Medical University · CNThird Hospital of Hebei Medical University · CN
Funding
The Key Research and Development Program of Hebei Province 19277779DThe Program of Introduce International Intelligence of Hebei ProvinceThe Project of Provincial Subsidy Fund (Construction of Key Traditional Chinese Medicine Disciplines) for Inheritance and Development of Traditional Chinese Medicine in 2022
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, HepatocellularHepatitis BLiver Neoplasmsalpha-FetoproteinsBiomarkers, TumorEndoplasmic ReticulumGolgi ApparatusHepatitis B virusHumansLiver CirrhosisROC CurveVesicular Transport Proteinsalpha-FetoproteinsBiomarkers, TumorSEC16A protein, humanVesicular Transport ProteinsDiagnosisDifferential diagnosisHepatitis B virusHepatocellular carcinomaLiver cirrhosisScaffold proteinSec16A
Identifiers
PMID37400387
PMCPMC12850662
OpenAlexW4383058436
What OpenQuestion holds
Textmetadata
Read underepoch 390